KYMR Q4 2022 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+5.7% YoY

Gross Profit

$16M100.0% margin

Operating Income

-$39M-239.4% margin

Net Income

-$35M-216.0% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+69.0%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$603M

Total Liabilities

$113M

Stockholders' Equity

$490M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$15M	+5.7%
Gross Profit	$16M	$15M	+5.7%
Operating Income	-$39M	-$34M	-13.6%
Net Income	-$35M	-$34M	-2.8%